Rani Therapeutics' net loss narrows in Q4 as costs fall

Overview

• U.S. biotherapeutics developer's Q4 net loss narrowed as operating expenses declined

• Company completed $60.3 mln private placement and entered $1.085 bln Chugai collaboration

• Company repaid all outstanding debt, strengthening balance sheet

Outlook

• Company expects cash reserves to fund operations into Q4 2027

• Rani expects R&D expenses to increase as it resumes programs and invests in platform development

• Company plans to advance clinical, strategic, and partnership objectives in 2026

Result Drivers

• COST CONTAINMENT - Co attributed lower R&D and G&A expenses to cost containment efforts, including reduced compensation and pausing or terminating certain R&D programs

• CLINICAL ADVANCEMENT - Co initiated Phase 1 study of RT-114, its first oral GLP-1/GLP-2 dual agonist, marking a milestone in clinical development

• PRECLINICAL DATA - Co released preclinical data showing successful oral delivery of semaglutide and bioequivalence of RT-114 via RaniPill platform

Company press release: ID:nGNX4QpgpX

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $8.00, about 601.8% above its March 25 closing price of $1.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.